| Title: |
The comorbidity and co-medication profile of patients with progressive supranuclear palsy |
| Authors: |
Greten, S.; Wegner, F.; Jensen, I.; Krey, L.; Rogozinski, S.; Fehring, M.; Heine, J.; Doll-Lee, J.; Pötter-Nerger, M.; Zeitzschel, M.; Hagena, K.; Pedrosa, D.J.; Eggers, C.; Bürk, K.; Trenkwalder, C.; Claus, I.; Warnecke, T.; Süß, P.; Winkler, J.; Gruber, D.; Gandor, F.; Berg, D.; Paschen, S.; Classen, J.; Pinkhardt, E.H.; Kassubek, J.; Jost, W.H.; Tönges, L.; Kühn, A.A.; Schwarz, J.; Peters, O.; Dashti, E.; Priller, J.; Spruth, E.J.; Krause, P.; Spottke, A.; Schneider, A.; Beyle, A.; Kimmich, O.; Donix, M.; Haussmann, R.; Brandt, M.; Dinter, E.; Wiltfang, J.; Schott, B.H.; Zerr, I.; Bähr, M.; Buerger, K.; Janowitz, D.; Perneczky, R.; Rauchmann, B.-S.; Weidinger, E.; Levin, J.; Katzdobler, S.; Düzel, E.; Glanz, W.; Teipel, S.; Kilimann, I.; Prudlo, J.; Gasser, T.; Brockmann, K.; Hoffmann, D.C.; Klockgether, T.; Krause, O.; Heck, J.; Höglinger, G.U.; Klietz, M. |
| Publisher Information: |
Springer Science and Business Media LLC |
| Publication Year: |
2024 |
| Collection: |
White Rose Research Online (Universities of Leeds, Sheffield & York) |
| Description: |
Background Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients. Objectives To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease. Methods Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug–drug interactions were evaluated using AiDKlinik®. Results In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug–drug interactions was higher in PSP patients, especially severe and moderate interactions. Conclusions PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients. |
| Document Type: |
article in journal/newspaper |
| File Description: |
text |
| Language: |
English |
| ISSN: |
0340-5354 |
| Relation: |
https://eprints.whiterose.ac.uk/id/eprint/207845/1/s00415-023-12006-4.pdf; Greten, S. orcid.org/0000-0003-0638-8571 , Wegner, F., Jensen, I. et al. (64 more authors) (2024) The comorbidity and co-medication profile of patients with progressive supranuclear palsy. Journal of Neurology, 271 (2). pp. 782-793. ISSN: 0340-5354 |
| DOI: |
10.1007/s00415-023-12006-4 |
| Availability: |
https://eprints.whiterose.ac.uk/id/eprint/207845/; https://doi.org/10.1007/s00415-023-12006-4 |
| Rights: |
cc_by_4 |
| Accession Number: |
edsbas.2534B8C8 |
| Database: |
BASE |